Rosuvastatin: effects on the liver and kidneys

Rosuvastatin is one of the most potent statins available on the NHS, widely prescribed to lower LDL cholesterol and reduce cardiovascular risk. Patients often ask whether it harms the liver or the kidneys, especially if they train hard or already take other medicines. Our editorial team reviews the evidence, the official UK labelling and the monitoring that keeps treatment safe.

What rosuvastatin is and how it works

Rosuvastatin belongs to the statin class, drugs that inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver. When hepatic cholesterol production falls, liver cells increase the number of LDL receptors on their surface and clear more LDL cholesterol from the blood. The result is a substantial reduction in LDL, a modest rise in HDL and a fall in triglycerides.

Compared with older statins, rosuvastatin is relatively hydrophilic and is taken up into liver cells mainly through specific transporters rather than passive diffusion. It is only minimally metabolised by the cytochrome P450 system, which means it has fewer interactions with drugs that affect CYP3A4 than simvastatin or atorvastatin. Most of the drug is eliminated unchanged in the faeces, with around a tenth excreted by the kidneys.

In the UK, rosuvastatin is a prescription-only medicine. NICE guidance on cardiovascular risk reduction lists it among the high-intensity statin options, alongside atorvastatin, for people who need a large LDL reduction. Licensed tablet strengths range from 5 mg to 40 mg, and the summary of product characteristics (SmPC) advises starting at a lower dose in certain groups, including people of Asian ancestry and those with moderate kidney impairment.

Large outcome trials, such as JUPITER, and the meta-analyses of the Cholesterol Treatment Trialists' Collaboration have shown that lowering LDL with statins reduces heart attacks and strokes. Questions about organ safety therefore have to be weighed against a well-established benefit.

Effects on the liver

Because statins act in the liver, it is natural to worry about hepatotoxicity. In practice, the most common finding is a mild, asymptomatic rise in the liver enzyme alanine aminotransferase (ALT). This is seen in a small proportion of patients, is more frequent at higher doses, and often settles even if treatment continues. It is generally regarded as an adaptive response rather than true liver injury.

Clinically significant liver damage from statins is rare. A Swedish analysis of post-marketing reports by Björnsson and colleagues identified statin-associated idiosyncratic liver injury as an uncommon event, with cases described for several statins including rosuvastatin. The American Heart Association's 2019 scientific statement on statin safety concluded that serious hepatotoxicity is very rare and that routine periodic liver testing in people without symptoms is not necessary in most cases.

The UK SmPC states that rosuvastatin is contraindicated in active liver disease, including unexplained persistent elevations of transaminases or any rise above three times the upper limit of normal. It also advises caution in people who drink substantial amounts of alcohol or have a history of liver disease.

Interestingly, people with non-alcoholic fatty liver disease, now often called metabolic dysfunction-associated steatotic liver disease (MASLD), are at high cardiovascular risk and generally benefit from statins. European guidance considers statins safe in this group, and observational data suggest they are not associated with worsening liver outcomes. The decision is individual, but fatty liver alone is not a reason to avoid treatment.

Effects on the kidneys

The kidney question has a longer history with rosuvastatin than with other statins. During its development, protein in the urine (proteinuria), mainly of tubular origin, was observed more often at the highest dose. The SmPC notes that this was mostly transient and was not, in general, predictive of acute or progressive kidney disease, but it is one reason why the 40 mg dose carries additional restrictions.

A large US cohort study published in 2022 by Shin and colleagues compared rosuvastatin with atorvastatin and found that rosuvastatin was associated with a higher risk of haematuria and proteinuria, and, at high doses, of kidney failure requiring replacement therapy. The authors also noted that many patients with reduced kidney function received doses above those recommended in the labelling. As an observational analysis it cannot prove causation, but it reinforced the importance of matching the dose to kidney function.

Because a share of rosuvastatin is cleared renally and blood levels rise as kidney function declines, the UK SmPC contraindicates the drug in severe renal impairment (creatinine clearance below 30 ml/min) and contraindicates the 40 mg dose in moderate impairment. Lower starting doses are advised when kidney function is moderately reduced.

On the other side of the ledger, people with chronic kidney disease have markedly elevated cardiovascular risk. Statin therapy reduces major vascular events in many of them, and NICE recommends offering a statin to people with CKD. The key is not avoidance but appropriate selection and dosing, sometimes favouring atorvastatin, which relies less on renal clearance.

Monitoring: which tests and when

NICE recommends measuring liver transaminases before starting a statin, and repeating them within three months and at twelve months. If results are normal, further routine testing is not needed unless clinically indicated. A rise below three times the upper limit of normal is not, by itself, a reason to stop treatment.

Kidney function, measured as serum creatinine with an estimated glomerular filtration rate (eGFR), should be known before starting rosuvastatin, because it determines the appropriate dose. Many patients also have urine albumin-to-creatinine ratio checked as part of their wider cardiovascular or diabetes care.

A typical monitoring set looks like this:

1. Baseline: full lipid profile, ALT, eGFR, HbA1c and thyroid function if indicated.
2. At around three months: lipid profile to assess response, plus ALT.
3. At twelve months: ALT, then annual review of lipids and kidney function as part of routine care.
4. Creatine kinase only if unexplained muscle symptoms occur, or at baseline in people at higher risk of myopathy.

Patients should report dark urine, persistent nausea, yellowing of the skin or eyes, or unexplained muscle pain and weakness promptly. These symptoms are uncommon but warrant urgent assessment.

Exercise, supplements and interactions

For people who train, interpreting blood tests needs care. Intense or unaccustomed exercise, particularly eccentric or heavy resistance work, can raise creatine kinase and the enzyme AST, and sometimes ALT, for several days. Creatinine can also be higher in muscular individuals and in those taking creatine supplements, which may make kidney function appear worse on an eGFR report than it really is. Telling the clinician about recent training and supplement use helps avoid unnecessary alarm.

Muscle symptoms remain the most common reason people stop statins, although blinded trials suggest that many such symptoms are not caused by the drug itself. Rhabdomyolysis is very rare but serious; it is the main route by which statins could cause acute kidney injury. Very strenuous exercise, dehydration, hypothyroidism and interacting drugs increase the risk.

Relevant interactions for rosuvastatin include ciclosporin, certain HIV protease inhibitor combinations, gemfibrozil and some other drugs that inhibit liver uptake transporters. Antacids containing aluminium or magnesium can reduce absorption if taken at the same time. Warfarin effects may change when rosuvastatin is started or adjusted, so INR monitoring is advised.

Among supplements, red yeast rice contains monacolin K, which is chemically identical to lovastatin, so combining it with a prescribed statin duplicates the effect and adds risk. Evidence that coenzyme Q10 prevents statin muscle symptoms is inconsistent. Heavy alcohol use adds strain on the liver and should be avoided. Ordinary sports supplements such as whey protein are not known to interact with rosuvastatin.

Editorial team's conclusions

For most people, rosuvastatin is safe for the liver: mild enzyme rises can occur, but serious liver injury is very rare, and fatty liver disease is not usually a barrier to treatment.

Kidney safety is mainly a question of correct dosing. Proteinuria and higher renal risks have been linked chiefly to high doses and to doses not adjusted for reduced kidney function, which is why baseline eGFR matters.

Simple monitoring at the start and during the first year, plus awareness of how exercise and creatine affect test results, allows active people to use rosuvastatin with confidence.

Related reading on our site includes how to interpret liver function tests after training, creatinine and eGFR in people who use creatine, and statins and muscle symptoms in athletes.

References

1. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81.
2. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–380.
3. Shin JI, Fine DM, Sang Y, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol. 2022;33(9):1767–1777.
4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
5. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
7. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238. London: NICE; 2023.
8. https://gearinjectuk.com/products/ultima-n-acetyl-semax-30mg-ultima-pharmaceuticals/